One of the principal challenges for both meningococcal vaccine developers and regulators is the development of a suitable strategy for the evaluation of functional antibody responses to new protein...
No takes yet. Share an insight, caveat, or question.
Ian M. Feavers (2009) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: